

ANNUAL BURDEN ESTIMATES

Instrument	Number of respondents	Number of responses per respondent	Average burden hours per response	Total burden hours
ADR .....	275	1	1	275

*Estimated Total Annual Burden Hours: 275.*

*Additional Information:* Copies of the proposed collection may be obtained by writing to the Administration for Children and Families, Office of Planning, Research and Evaluation, 330 C Street SW, Washington, DC 20201. Attention Reports Clearance Officer. All requests should be identified by the title of the information collection. Email address: [infocollection@acf.hhs.gov](mailto:infocollection@acf.hhs.gov).

*OMB Comment:* OMB is required to make a decision concerning the collection of information between 30 and 60 days after publication of this document in the **Federal Register**. Therefore, a comment is best assured of having its full effect if OMB receives it within 30 days of publication. Written comments and recommendations for the proposed information collection should be sent directly to the following: Office of Management and Budget, Paperwork Reduction Project, Email: [OIRA\\_SUBMISSION@OMB.EOP.GOV](mailto:OIRA_SUBMISSION@OMB.EOP.GOV); Attn: Desk Officer for the Administration for Children and Families.

**Robert A. Sargis,**  
Reports Clearance Officer.

[FR Doc. 2018-18495 Filed 8-24-18; 8:45 am]  
BILLING CODE 4184-34-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Meeting of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria**

**AGENCY:** Department of Health and Human Services, Office of the Secretary, Office of the Assistant Secretary for Health.

**ACTION:** Notice.

**SUMMARY:** As stipulated by the Federal Advisory Committee Act, the Department of Health and Human Services (HHS) is hereby giving notice that a meeting is scheduled to be held for the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria (Advisory Council). The meeting will be open to the public; a public comment session will be held during the meeting. Pre-registration is required for members of the public who wish to attend the meeting and who wish to participate in

the public comment session. Individuals who wish to attend the meeting and/or send in their public comment via email should send an email to [CARB@hhs.gov](mailto:CARB@hhs.gov). Registration information is available on the website <http://www.hhs.gov/ash/carb/> and must be completed by September 19, 2018; all in-person attendees must pre-register by this date. Additional information about registering for the meeting and providing public comment can be obtained at <http://www.hhs.gov/ash/carb/> on the Meetings page.

**DATES:** The meeting is scheduled to be held on September 26, 2018, from 9:00 a.m. to 5:00 p.m. ET (times are tentative and subject to change). The confirmed times and agenda items for the meeting will be posted on the website for the Advisory Council at <http://www.hhs.gov/ash/carb/> when this information becomes available. Pre-registration for attending the meeting in person is required to be completed no later than September 19, 2018; public attendance at the meeting is limited to the available space.

**ADDRESSES:** This public meeting is being held at the Sheraton Columbus Hotel at Capitol Square, 75 East State Street, Columbus, OH, 43215. The meeting can also be accessed through a live webcast on the day of the meeting. For more information, visit <http://www.hhs.gov/ash/carb/>.

**FOR FURTHER INFORMATION CONTACT:** Jomana Musmar, Acting Designated Federal Officer, Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria, Office of the Assistant Secretary for Health, U.S. Department of Health and Human Services, Room 715H, Hubert H. Humphrey Building, 200 Independence Avenue SW, Washington, DC 20201. Phone: (202) 690-5566; email: [CARB@hhs.gov](mailto:CARB@hhs.gov).

**SUPPLEMENTARY INFORMATION:** Under Executive Order 13676, dated September 18, 2014, authority was given to the Secretary of HHS to establish the Advisory Council, in consultation with the Secretaries of Defense and Agriculture. Activities of the Advisory Council are governed by the provisions of Public Law 92-463, as amended (5 U.S.C. App.), which sets forth standards

for the formation and use of federal advisory committees.

The Advisory Council will provide advice, information, and recommendations to the Secretary of HHS regarding programs and policies intended to support and evaluate the implementation of Executive Order 13676, including the National Strategy for Combating Antibiotic-Resistant Bacteria and the National Action Plan for Combating Antibiotic-Resistant Bacteria. The Advisory Council shall function solely for advisory purposes.

In carrying out its mission, the Advisory Council will provide advice, information, and recommendations to the Secretary regarding programs and policies intended to preserve the effectiveness of antibiotics by optimizing their use; advance research to develop improved methods for combating antibiotic resistance and conducting antibiotic stewardship; strengthen surveillance of antibiotic-resistant bacterial infections; prevent the transmission of antibiotic-resistant bacterial infections; advance the development of rapid point-of-care and agricultural diagnostics; further research on new treatments for bacterial infections; develop alternatives to antibiotics for agricultural purposes; maximize the dissemination of up-to-date information on the appropriate and proper use of antibiotics to the general public and human and animal healthcare providers; and improve international coordination of efforts to combat antibiotic resistance.

The September 26, 2018, public meeting will be dedicated to the Advisory Council's deliberation and vote of the Infection Prevention and Stewardship Working Group's draft report with recommendations, in addition to other topic areas surrounding antibiotic-resistance and One Health. The meeting agenda will be posted on the Advisory Council website at <http://www.hhs.gov/ash/carb/> when it has been finalized. All agenda items are tentative and subject to change.

Public attendance at the meeting is limited to the available space. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Advisory Council at the

address/telephone number listed above at least one week prior to the meeting. For those unable to attend in person, a live webcast will be available. More information on registration and accessing the webcast can be found at <http://www.hhs.gov/ash/carb/>.

Members of the public will have the opportunity to provide comments prior to the Advisory Council meeting by emailing [CARB@hhs.gov](mailto:CARB@hhs.gov). Public comments should be sent in by midnight September 19, 2018, and should be limited to no more than one page. All public comments received prior to September 19, 2018, will be provided to Advisory Council members; comments are limited to two minutes per speaker.

Dated: August 21, 2018.

**Jomana F. Musmar,**

*Acting Designated Federal Officer,  
Presidential Advisory Council on Combating  
Antibiotic-Resistant Bacteria Committee  
Manager.*

[FR Doc. 2018-18483 Filed 8-24-18; 8:45 am]

**BILLING CODE 4150-44-P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### National Institutes of Health

#### National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI SPORE III.

*Date:* September 19–20, 2018.

*Time:* 5:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Gaithersburg Marriott Washingtonian Center, 9751 Washingtonian Boulevard, Gaithersburg, MD 20878.

*Contact Person:* Wlodek Lopaczynski, M.D., Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W514, Bethesda, MD 20892-9750, 240-276-6340, [lopacw@mail.nih.gov](mailto:lopacw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP 4 for Provocative Questions.

*Date:* September 21, 2018.

*Time:* 7:30 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

*Contact Person:* Clifford W. Schweinfest, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W108, Bethesda, MD 20892-9750, 240-276-6343, [schweinfestcw@mail.nih.gov](mailto:schweinfestcw@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP-1 for Provocative Questions.

*Date:* October 4, 2018.

*Time:* 7:30 a.m. to 4:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Cambria Hotel Rockville, 1 Helen Heneghan Way, Rockville, MD 20850.

*Contact Person:* Hasan Siddiqui, Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W240, Bethesda, MD 20892-9750, 240-276-5122, [hasan.siddiqui@nih.gov](mailto:hasan.siddiqui@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP-3 for Provocative Questions.

*Date:* October 9, 2018.

*Time:* 8:00 a.m. to 6:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852.

*Contact Person:* Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Bethesda, MD 20892-9750, 240-276-6368, [Stoicaa2@mail.nih.gov](mailto:Stoicaa2@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; Traceback Testing; Identification and Genetic Counseling of Mutation Carriers (U01).

*Date:* October 10, 2018.

*Time:* 11:00 a.m. to 1:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W248, Rockville, MD 20850 (Telephone Conference Call).

*Contact Person:* Anita T. Tandle, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W248, Bethesda, MD 20892-9750, 240-276-5007, [tandlea@mail.nih.gov](mailto:tandlea@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP-5 for Provocative Questions.

*Date:* October 18–19, 2018.

*Time:* 6:00 p.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* Bethesda Marriott Suites, 6711 Democracy Boulevard, Bethesda, MD 20817.

*Contact Person:* Byeong-Chel Lee, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Bethesda, MD 20892-9750, 240-276-7755, [byeong-chel.lee@nih.gov](mailto:byeong-chel.lee@nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; SEP-1 NCI Clinical and Translational R21 and Omnibus R03.

*Date:* October 25, 2018.

*Time:* 10:00 a.m. to 5:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W242, Rockville, MD 20850 (Telephone Conference Call).

*Contact Person:* Zhiqiang Zou, M.D., Ph.D., Scientific Review Officer, Special Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W242, Bethesda, MD 20892-9750, 240-276-6372, [zouzhiq@mail.nih.gov](mailto:zouzhiq@mail.nih.gov).

*Name of Committee:* National Cancer Institute Special Emphasis Panel; NCI U01 Review: Integrating Biospecimens into Clinical Assay Development.

*Date:* November 15, 2018.

*Time:* 12:00 p.m. to 2:00 p.m.

*Agenda:* To review and evaluate grant applications.

*Place:* National Cancer Institute, Shady Grove, 9609 Medical Center Drive, Room 7W116, Rockville, MD 20850 (Telephone Conference Call).

*Contact Person:* Klaus B. Piontek, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W116, Bethesda, MD 20892-9750, 240-276-7849, [klaus.piontek@nih.gov](mailto:klaus.piontek@nih.gov).

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: August 20, 2018.

**Melanie J. Pantoja,**

*Program Analyst, Office of Federal Advisory  
Committee Policy.*

[FR Doc. 2018-18399 Filed 8-24-18; 8:45 am]

**BILLING CODE 4140-01-P**